List of Complera drug patents

Complera is owned by Gilead Sciences Inc.

Complera contains Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Disoproxil Fumarate.

Complera has a total of 9 drug patents out of which 1 drug patent has expired.

Expired drug patents of Complera are:

  • US8101629

Complera was authorised for market use on 10 August, 2011.

Complera is available in tablet;oral dosage forms.

Complera can be used as treatment of hiv infection.

The generics of Complera are possible to be released after 14 January, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2023

(2 months from now)

US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629 GILEAD SCIENCES INC Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(5 months ago)

US8716264 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9744181 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US8592397 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9457036 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US8841310 GILEAD SCIENCES INC Combinations of a pyrimidine containing NNRTI with RT inhibitors
Dec, 2025

(2 years from now)

US10857102 GILEAD SCIENCES INC Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
Jan, 2033

(9 years from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 10 August, 2011

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of COMPLERA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in